Prostate cancer often manifests as a multifocal disease; it is hard to reli­ably visualize with conventional imaging, and it exhibits various pathological forms and subtypes, each with distinct (but not completely understood) clini­cal behaviors. The current standard of care in the management of localized prostate cancer is considered active surveillance for low-risk and surgery or radiation therapy for intermediate and high-risk cases. However, unlike sur­veillance with almost no side effects, surgery and radiation adverse effects surge signicantly, which can compromise the patient’s quality of life. While such a detrimental effect might be justiable for high-risk prostate cancer, particularly if it is curative, the optimal management strategy for intermediate­risk disease is needed. Focal therapy aims to ll this void as it is considered an extension of surveillance, treating the cancerous part with the hope of delaying metastasis and radical treatment. The lower side effect prole of focal therapy, compared to radical treatments and subsequently providing a better quality of life, caused focal therapy to pique curiosity and gain interest in recent years up to the point that almost all top-rated medical universities have published patient information webpages on prostate focal therapy. Today, if a urologist or oncologist does not counsel her/his prostate cancer patients regarding focal therapy, they have probably broken informed